舒马曲坦联合左乙拉西坦治疗顽固性偏头痛的疗效及对血浆5-羟色胺水平的影响  

Effect of Sumatriptan Combined with Levetiracetam in the Treatment of Intractable Migraine and Its Influence on Plasma 5-Hydroxytrypamine Level

作　　者：展波涛 ZHAN Botao(Department of Internal Medicine,Zhoukou Center for Disease Control and Prevention Specialist Hospital,Zhoukou Henan 466000,China)

机构地区：[1]周口市疾病预防控制中心专科病医院内科,河南周口466000

出　　处：《药品评价》2020年第14期31-32,35,共3页Drug Evaluation

摘　　要：目的:观察舒马曲坦联合左乙拉西坦治疗顽固性偏头痛的效果及对患者血浆5-羟色胺水平的影响。方法:选取2018年4月—2020年1月本院收治的100例顽固性偏头痛患者为观察对象,随机分成观察组和对照组各50例。对照组采用舒马曲坦治疗,观察组采用舒马曲坦联合左乙拉西坦治疗,比较两组患者的治疗效果及治疗前后血浆5-羟色胺含量的变化。结果:治疗后,总有效率观察组明显高于对照组,血浆5-羟色胺含量观察组明显高于对照组,组间差异均有统计学意义(P<0.05)。结论:舒马曲坦联合左乙拉西坦治疗顽固性偏头痛可提高治疗效果、改善血浆5-羟色胺水平,有临床应用价值。Objective:To observe the effect of sumatriptan combined with levetiracetam in the treatment of intractable migraine and its influence on plasma 5-hydroxytryptamine level.Methods:100 patients with intractable migraine in our hospital from April 2018 to January 2020 were selected as the observation objects and randomly divided into observation group and control group with 50 cases in each group.The control group was treated with sumatriptan,and the observation group was treated with sumatriptan combined with levetiracetam.The therapeutic effect and the changes of plasma 5-hydroxytryptamine before and after treatment were compared between the two groups.Results:After treatment,the total effective rate of the observation group was significantly higher than that of the control group,and the plasma 5-hydroxytryptamine content of the observation group was significantly higher than that of the control group,and the differences between the two groups were statistically significant(P<0.05).Conclusion:Sumatriptan combined with levetiracetam in the treatment of intractable migraine can improve the therapeutic effect and Plasma 5-HT level.

关 键 词：顽固性偏头痛 血浆5-羟色胺 舒马曲坦 左乙拉西坦 

分 类 号：R747.2[医药卫生—神经病学与精神病学]